Moderna Provides Update on Norovirus Vaccine Candidate
2 days ago · Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. It is currently being evaluated in the randomized, observer-blinded, placebo-controlled phase 3 Nova 301 trial (ClinicalTrials.gov Identifier: NCT06592794 ) for the prevention of moderate or severe acute ...
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
Sep 30, 2024 · The vaccine candidate is a trivalent formulation containing mRNA that encodes for virus-like particles (VLPs) designed to protect against multiple norovirus genotypes. About Moderna. Moderna is a leader in the creation of the field of mRNA medicine.
Norovirus vaccine from Moderna could have Phase 3 results this …
4 days ago · Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.
From Covid to Norovirus: Moderna’s mRNA Tech Takes on
Jan 20, 2025 · Moderna’s vaccine candidate, for instance, tries to create immunity by training the body to target virus-like particles (VLPs) that closely resemble norovirus but which contain no actual virus.
A genetic quirk protects some people from norovirus. Can vaccines ... - BBC
Dec 31, 2024 · Moderna have launched a clinical trial of a messenger RNA (mRNA) norovirus vaccine initially in 18-49 year olds and 60-80 year olds. Meanwhile, Boston-based biotech HilleVax is conducting...
Moderna says it’s ‘one step closer’ to a norovirus ... - Yahoo
Jan 13, 2025 · Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403. “Stomach bug,” “cruise-ship virus,” “winter...
A Norovirus Vaccine Is in the Works | TIME
Jan 10, 2025 · But scientists at Moderna are in the late stages of testing what could be the first such shot, using mRNA technology against the virus. Here’s what to know about norovirus and where things...
News Details - Moderna
Mar 27, 2024 · Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms.
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
Moderna doses first subject in mRNA norovirus vaccine trial
Oct 1, 2024 · US-based pharmaceutical company Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403. The Nova 301 trial aims to evaluate the vaccine’s efficacy, safety …